Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database.

ABSTRACT:

Background

Selpercatinib, a highly selective tyrosine kinase inhibitor, has emerged as an excellent treatment option for patients with rearranged during transfection-altered cancer. However, there is limited comprehensive safety information available for selpercatinib through large-scale post-marketing monitoring.

Methods

This study conducted a comprehensive analysis of selpercatinib-related adverse events (AEs) using the FDA Adverse Event Reporting System database. Four disproportionality methods were employed to identify potential AEs associated with selpercatinib. Specifically, this study investigated the differences in AEs of selpercatinib with respect to reporter continent, indication, sex, age, weight, dose, frequency, and onset time.

Results

A total of 464 repo

SUBMITTER: Qian J 

PROVIDER: S-EPMC11613847 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature